Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Protection by 4th dose of BNT162b2 against Omicron in Israel

Yinon M. Bar-On, Yair Goldberg, Micha Mandel, Omri Bodenheimer, Ofra Amir, Laurence Freedman, Sharon Alroy-Preis, Nachman Ash, Amit Huppert, Ron Milo
doi: https://doi.org/10.1101/2022.02.01.22270232
Yinon M. Bar-On
1Department of Plant and Environmental Sciences, Weizmann Institute of Science, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yair Goldberg
2Technion - Israel Institute of Technology, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yairgo{at}technion.ac.il
Micha Mandel
3The Hebrew University of Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omri Bodenheimer
4Israel Ministry of Health, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ofra Amir
2Technion - Israel Institute of Technology, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence Freedman
5The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Alroy-Preis
4Israel Ministry of Health, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nachman Ash
4Israel Ministry of Health, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Huppert
5The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Israel
6The Faculty of Medicine, Tel Aviv University, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ron Milo
1Department of Plant and Environmental Sciences, Weizmann Institute of Science, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

BACKGROUND On January 2, 2022, Israel began administering a fourth dose of BNT162b2 vaccine (Pfizer-BioNTech) to people aged over 60 years and at-risk populations, who had received a third dose of vaccine at least 4 months earlier. The effect of the fourth dose on confirmed coronavirus 2019 disease (Covid-19) and severe illness are still unclear.

METHODS We extracted data for the Omicron-dominated period January 15 through January 27, 2022, from the Israeli Ministry of Health database regarding 1,138,681 persons aged over 60 years and eligible for the fourth dose. We compared the rate of confirmed Covid-19 and severe illness between those who had received a fourth dose at least 12 days earlier, those who had received only three doses, and those 3 to 7 days after receiving the fourth dose. We used Poisson regression after adjusting for possible confounding factors.

RESULTS The rate of confirmed infection was lower in people 12 or more days after their fourth dose than among those who received only three doses and those 3 to 7 days after vaccination by factors of 2.0 (95% confidence interval [CI], 2.0 to 2.1) and 1.9 (95% CI, 1.8 to 2.0), respectively. The rate of severe illness was lower by factors of 4.3 (95% CI, 2.4 to 7.6) and 4.0 (95% CI, 2.2 to 7.5).

CONCLUSIONS Rates of confirmed Covid-19 and severe illness were lower following a fourth dose compared to only three doses.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Institutional Review Board of the Sheba Medical Center. Helsinki approval number: SMC-8228-21.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The individual-level data used in this study cannot be publicly shared even if anonymized due to privacy restrictions.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 01, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Protection by 4th dose of BNT162b2 against Omicron in Israel
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Protection by 4th dose of BNT162b2 against Omicron in Israel
Yinon M. Bar-On, Yair Goldberg, Micha Mandel, Omri Bodenheimer, Ofra Amir, Laurence Freedman, Sharon Alroy-Preis, Nachman Ash, Amit Huppert, Ron Milo
medRxiv 2022.02.01.22270232; doi: https://doi.org/10.1101/2022.02.01.22270232
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Protection by 4th dose of BNT162b2 against Omicron in Israel
Yinon M. Bar-On, Yair Goldberg, Micha Mandel, Omri Bodenheimer, Ofra Amir, Laurence Freedman, Sharon Alroy-Preis, Nachman Ash, Amit Huppert, Ron Milo
medRxiv 2022.02.01.22270232; doi: https://doi.org/10.1101/2022.02.01.22270232

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3295)
  • Dentistry and Oral Medicine (364)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13381)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5155)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3271)
  • Health Policy (1142)
  • Health Systems and Quality Improvement (1192)
  • Hematology (431)
  • HIV/AIDS (1018)
  • Infectious Diseases (except HIV/AIDS) (14632)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4928)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (726)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4216)
  • Public and Global Health (7506)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1014)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)